Katherine Wolf
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Katherine Wolf has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
- Tobias Else
Department of Internal Medicine, Division of Metabolism, Endocrinology, and Diabetes, University of Michigan, Ann Arbor, MI, USA
3 shared publications Elizabeth A Hesseltine
Department of Internal Medicine, Division of Hematology & Oncology, University of Michigan, Ann Arbor, MI, USA
2 shared publicationsFrancis P Worden
Department of Internal Medicine, Division of Hematology & Oncology, University of Michigan, Ann Arbor, MI, USA
2 shared publicationsJenae Osborne
Department of Internal Medicine, Division of Genetic Medicine, Michigan Medicine, Ann Arbor, MI, United States
2 shared publications- Amy Thees
Rosalind Franklin University of Medicine and Science, Clinical Immunology Laboratory, North Chicago, IL
1 shared publication Antonio M Lerario
Department of Internal Medicine, Division of Metabolism, Endocrinology, & Diabetes, Endocrine Oncology Program, Michigan Medicine, Ann Arbor, MI, United States
1 shared publication
Latest Publications
- 1 March 2026
- Published by Bioscientifica in Endocrine-Related Cancer
- Vol. 33 (3)
Adrenocortical carcinoma as a manifestation of Birt–Hogg–Dubé syndrome
Birt–Hogg–Dubé syndrome (BHDS) is characterized by fibrofolliculomas, trichodiscomas, renal tumors, lung cysts, and spontaneous pneumothoraces. Other than renal cell carcinoma, no cancers have been confirmed as part of the BHDS tumor spectrum. Here, we set out to uncover if adrenocortical carcinoma (ACC) is associated with BHDS. A retrospective review at a single tertiary care center between 2010 and 2024 was performed using search terms describing the clinical manifestations of BHDS, adrenal tumors, and iterations thereof. The initial review identified 1,010 patients with ACC. Of these patients, 466 were evaluated by a genetic counselor, and 346 underwent genetic testing—seven of which were found to have either characteristic clinical features of BHDS or a confirmed diagnosis. The literature review over the same time period demonstrated five additional cases of malignant adrenal tumors in patients with BHDS. We observed BHDS, confirmed by a pathogenic FLCN variant in 0.7% of all ACC patients, or 1.5% of patients evaluated by a genetic counselor and 2.0% of all patients who underwent genetic testing. Testing for FLCN pathogenic variants should be considered during routine genetic evaluation of patients with ACC, and special attention should be paid to adrenal tumors in BHDS patients during surveillance for renal neoplasms as more than 50% of patients in this series developed metastatic disease.
- 1 March 2026
- Published by Bioscientifica in Endocrine-Related Cancer
- Vol. 33 (3)
Adrenocortical carcinoma as a manifestation of Birt–Hogg–Dubé syndrome
Birt–Hogg–Dubé syndrome (BHDS) is characterized by fibrofolliculomas, trichodiscomas, renal tumors, lung cysts, and spontaneous pneumothoraces. Other than renal cell carcinoma, no cancers have been confirmed as part of the BHDS tumor spectrum. Here, we set out to uncover if adrenocortical carcinoma (ACC) is associated with BHDS. A retrospective review at a single tertiary care center between 2010 and 2024 was performed using search terms describing the clinical manifestations of BHDS, adrenal tumors, and iterations thereof. The initial review identified 1,010 patients with ACC. Of these patients, 466 were evaluated by a genetic counselor, and 346 underwent genetic testing—seven of which were found to have either characteristic clinical features of BHDS or a confirmed diagnosis. The literature review over the same time period demonstrated five additional cases of malignant adrenal tumors in patients with BHDS. We observed BHDS, confirmed by a pathogenic FLCN variant in 0.7% of all ACC patients, or 1.5% of patients evaluated by a genetic counselor and 2.0% of all patients who underwent genetic testing. Testing for FLCN pathogenic variants should be considered during routine genetic evaluation of patients with ACC, and special attention should be paid to adrenal tumors in BHDS patients during surveillance for renal neoplasms as more than 50% of patients in this series developed metastatic disease.
- 1 January 2026
- Published by Bioscientifica in Endocrine-Related Cancer
- Vol. 33 (1)
Prevalence and clinical characteristics of Lynch syndrome-associated adrenocortical carcinoma
Lynch syndrome is the result of pathogenic variants in mismatch repair genes that increase the risk of cancer, including adrenocortical carcinoma. Little is known, however, about the clinical characteristics of patients with Lynch syndrome-associated adrenocortical carcinoma. In order to understand the clinical characteristics and prevalence of Lynch syndrome-associated adrenocortical carcinoma, we conducted a retrospective chart review of patients with adrenocortical carcinoma and germline genetic testing results, indicating pathogenic variants in mismatch repair genes consistent with Lynch syndrome at a single academic tertiary-care institution. In total, 21 patients with Lynch syndrome-associated adrenocortical carcinoma were identified from 2003 to 2024. Three patients met Amsterdam I criteria, and 12 patients met Amsterdam II criteria (including adrenocortical carcinoma as a Lynch syndrome-associated cancer). More than 90% of patients with available histopathology had high-grade tumors, suggesting a more aggressive nature. The prevalence of Lynch syndrome-associated adrenocortical carcinoma is estimated at 2.6%. This study further demonstrates that adrenocortical carcinoma is a Lynch syndrome-associated cancer and may be associated with a high-grade disease. Furthermore, our findings suggest that further research should be pursued to investigate the potential utility of immunotherapy for adrenocortical carcinoma, especially in the presence of microsatellite instability.
- 1 January 2026
- Published by Bioscientifica in Endocrine-Related Cancer
- Vol. 33 (1)
Prevalence and clinical characteristics of Lynch syndrome-associated adrenocortical carcinoma
Lynch syndrome is the result of pathogenic variants in mismatch repair genes that increase the risk of cancer, including adrenocortical carcinoma. Little is known, however, about the clinical characteristics of patients with Lynch syndrome-associated adrenocortical carcinoma. In order to understand the clinical characteristics and prevalence of Lynch syndrome-associated adrenocortical carcinoma, we conducted a retrospective chart review of patients with adrenocortical carcinoma and germline genetic testing results, indicating pathogenic variants in mismatch repair genes consistent with Lynch syndrome at a single academic tertiary-care institution. In total, 21 patients with Lynch syndrome-associated adrenocortical carcinoma were identified from 2003 to 2024. Three patients met Amsterdam I criteria, and 12 patients met Amsterdam II criteria (including adrenocortical carcinoma as a Lynch syndrome-associated cancer). More than 90% of patients with available histopathology had high-grade tumors, suggesting a more aggressive nature. The prevalence of Lynch syndrome-associated adrenocortical carcinoma is estimated at 2.6%. This study further demonstrates that adrenocortical carcinoma is a Lynch syndrome-associated cancer and may be associated with a high-grade disease. Furthermore, our findings suggest that further research should be pursued to investigate the potential utility of immunotherapy for adrenocortical carcinoma, especially in the presence of microsatellite instability.
- Open Access
- 1 January 2025
- Published by Bioscientifica in Endocrine Oncology
- Vol. 5 (1)
Success of 177Lu-DOTATATE therapy in a metastatic pituitary neuroendocrine tumor
Metastatic pituitary neuroendocrine tumors (PitNETs) are rare and often aggressive. Patients should be evaluated for metastatic disease when their biochemical presentation is discordant with pituitary tumor burden or when they present with non-pituitary, site-specific symptoms. Here, we describe the case of a 55-year-old male with an ACTH-secreting PitNET and more than a decade of recurrent transsphenoidal resections, gamma knife irradiation, and therapy with somatostatin analogs and steroidogenesis inhibitors before uncovering metastatic osseous deposits. Only after initiation of peptide receptor radionuclide therapy (PRRT) with 177Lu DOTATATE has he had sustained clinical, biochemical, and structural improvement. There are a limited number of cases of patients with metastatic PitNET who underwent PRRT, but the majority have been favorable with limited adverse events, including hematologic cytopenias, and tumor stability and/or shrinkage. While there are several other off-label, novel therapies used in this population, including non-endocrine targeted therapies or immunotherapy, further studies should evaluate the earlier introduction of PRRT in metastatic PitNET given the good safety profile and overall clinical success. Learning points:
- 1 January 2025
- Published by Bioscientifica in Endocrine Oncology
- Vol. 5 (1)
Open AccessSuccess of 177Lu-DOTATATE therapy in a metastatic pituitary neuroendocrine tumor
Metastatic pituitary neuroendocrine tumors (PitNETs) are rare and often aggressive. Patients should be evaluated for metastatic disease when their biochemical presentation is discordant with pituitary tumor burden or when they present with non-pituitary, site-specific symptoms. Here, we describe the case of a 55-year-old male with an ACTH-secreting PitNET and more than a decade of recurrent transsphenoidal resections, gamma knife irradiation, and therapy with somatostatin analogs and steroidogenesis inhibitors before uncovering metastatic osseous deposits. Only after initiation of peptide receptor radionuclide therapy (PRRT) with 177Lu DOTATATE has he had sustained clinical, biochemical, and structural improvement. There are a limited number of cases of patients with metastatic PitNET who underwent PRRT, but the majority have been favorable with limited adverse events, including hematologic cytopenias, and tumor stability and/or shrinkage. While there are several other off-label, novel therapies used in this population, including non-endocrine targeted therapies or immunotherapy, further studies should evaluate the earlier introduction of PRRT in metastatic PitNET given the good safety profile and overall clinical success. Learning points:
- Open Access
- 7 November 2024
- Published by The Endocrine Society in JCEM Case Reports
- Vol. 2 (12) , luae209
Calcitriol-Mediated Hypercalcemia Due to Liver Metastases in a Patient With Primary Pancreatic Neuroendocrine Tumor
Hypercalcemia is most commonly associated with primary hyperparathyroidism or malignancy in the setting of elevated parathyroid hormone-related protein or bone metastases. Calcitriol (1,25-dihydroxyvitamin D)-mediated hypercalcemia is rare and typically associated with granulomatous conditions; however, other solid-organ etiologies have been reported. Here, we detail the case of a 62-year-old man with metastatic pancreatic neuroendocrine tumor (pNET) with hypercalcemia refractory to traditional bisphosphonate therapy in the setting of vastly elevated 1,25-dihydroxyvitamin D. Only after initiation of chemotherapy with capecitabine and temozolomide did his serum calcium consistently improve and 1,25-dihydroxyvitamin D begin to decrease. There are fewer than 5 reported cases of a pNET resulting in calcitriol-mediated hypercalcemia. Prompt initiation of treatment for the underlying condition can result in a significant improvement in serum calcium or 1,25-dihydroxyvitamin D. Multiple reports have also demonstrated success with high-dose steroid administration in patients with other solid-organ etiologies of calcitriol-mediated hypercalcemia, but this has not yet been reviewed in the pNET population.
- 7 November 2024
- Published by The Endocrine Society in JCEM Case Reports
- Vol. 2 (12) , luae209
Open AccessCalcitriol-Mediated Hypercalcemia Due to Liver Metastases in a Patient With Primary Pancreatic Neuroendocrine Tumor
Hypercalcemia is most commonly associated with primary hyperparathyroidism or malignancy in the setting of elevated parathyroid hormone-related protein or bone metastases. Calcitriol (1,25-dihydroxyvitamin D)-mediated hypercalcemia is rare and typically associated with granulomatous conditions; however, other solid-organ etiologies have been reported. Here, we detail the case of a 62-year-old man with metastatic pancreatic neuroendocrine tumor (pNET) with hypercalcemia refractory to traditional bisphosphonate therapy in the setting of vastly elevated 1,25-dihydroxyvitamin D. Only after initiation of chemotherapy with capecitabine and temozolomide did his serum calcium consistently improve and 1,25-dihydroxyvitamin D begin to decrease. There are fewer than 5 reported cases of a pNET resulting in calcitriol-mediated hypercalcemia. Prompt initiation of treatment for the underlying condition can result in a significant improvement in serum calcium or 1,25-dihydroxyvitamin D. Multiple reports have also demonstrated success with high-dose steroid administration in patients with other solid-organ etiologies of calcitriol-mediated hypercalcemia, but this has not yet been reviewed in the pNET population.
- Open Access
- 21 September 2022
- Published by Open Exploration Publishing in Exploration of Immunology
- Vol. 2 (5) , 693-722
Natural killer cell-mediated immunopathology in recurrent pregnancy losses
Natural killer (NK) cells have a dual role in human reproduction for maternal-fetal tolerance and protection from infection. During the ovarian cycle and pregnancy, peripheral NK (pNK) and uterine NK (uNK) cells dynamically change their proportions and cytotoxicities to prepare and accommodate invading trophoblast and maintain pregnancy. However, dysregulated pNK and uNK cell proportions and cytotoxic activities have been associated with aberrant spiral artery remodeling and trophoblast invasion, leading to implantation failures and recurrent pregnancy losses (RPLs). This review will focus on the role of NK cells in RPLs reviewing the ontogeny of NK cells, changes in pNK and uNK cell levels, and activities during the ovarian cycle, normal pregnancy, and RPL. In addition, the immunopathological role of NK cells in endometrial/decidual vascular development and killer immunoglobin-like receptor (KIR) and human leukocyte antigen (HLA)-C interactions are discussed.
- 21 September 2022
- Published by Open Exploration Publishing in Exploration of Immunology
- Vol. 2 (5) , 693-722
Open AccessNatural killer cell-mediated immunopathology in recurrent pregnancy losses
Natural killer (NK) cells have a dual role in human reproduction for maternal-fetal tolerance and protection from infection. During the ovarian cycle and pregnancy, peripheral NK (pNK) and uterine NK (uNK) cells dynamically change their proportions and cytotoxicities to prepare and accommodate invading trophoblast and maintain pregnancy. However, dysregulated pNK and uNK cell proportions and cytotoxic activities have been associated with aberrant spiral artery remodeling and trophoblast invasion, leading to implantation failures and recurrent pregnancy losses (RPLs). This review will focus on the role of NK cells in RPLs reviewing the ontogeny of NK cells, changes in pNK and uNK cell levels, and activities during the ovarian cycle, normal pregnancy, and RPL. In addition, the immunopathological role of NK cells in endometrial/decidual vascular development and killer immunoglobin-like receptor (KIR) and human leukocyte antigen (HLA)-C interactions are discussed.
- Open Access
- 5 September 2019
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 3 (11) , 2151-2157
A Family With a Carotid Body Paraganglioma and Thyroid Neoplasias With a New SDHAF2 Germline Variant
At least 30% of all pheochromocytomas/paragangliomas (PCCs/PGLs) arise in patients with a germline predisposition syndrome. Variants in succinate dehydrogenase subunits A, B, C, and D (SDHA, SDHB, SDHC, and SDHD) are the most common pathogenic germline alterations. Only very few pathogenic variants have been reported in succinate dehydrogenase assembly factor 2 (SDHAF2). Here, we describe a 30-year old female patient who presented with a left-sided neck mass, which was later characterized as a carotid body paraganglioma. Genetic testing revealed a likely pathogenic SDHAF2 variant (c.347G>A;p.W116X). Two sisters carried the same pathologic variant and screening protocols were recommended. Whole body magnetic resonance imaging revealed thyroid nodules, which were followed by fine needle aspiration that confirmed papillary thyroid carcinoma in one sister and a follicular adenoma in the other, which led to a hemithyroidectomy and total thyroidectomy, respectively. As evidence for pathogenic variants in SDHAF2 causing predisposition to PCC/PGL is limited, we discuss the challenges in mutational variant interpretation and decision making regarding screening for associated tumors.
- 5 September 2019
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 3 (11) , 2151-2157
Open AccessA Family With a Carotid Body Paraganglioma and Thyroid Neoplasias With a New SDHAF2 Germline Variant
At least 30% of all pheochromocytomas/paragangliomas (PCCs/PGLs) arise in patients with a germline predisposition syndrome. Variants in succinate dehydrogenase subunits A, B, C, and D (SDHA, SDHB, SDHC, and SDHD) are the most common pathogenic germline alterations. Only very few pathogenic variants have been reported in succinate dehydrogenase assembly factor 2 (SDHAF2). Here, we describe a 30-year old female patient who presented with a left-sided neck mass, which was later characterized as a carotid body paraganglioma. Genetic testing revealed a likely pathogenic SDHAF2 variant (c.347G>A;p.W116X). Two sisters carried the same pathologic variant and screening protocols were recommended. Whole body magnetic resonance imaging revealed thyroid nodules, which were followed by fine needle aspiration that confirmed papillary thyroid carcinoma in one sister and a follicular adenoma in the other, which led to a hemithyroidectomy and total thyroidectomy, respectively. As evidence for pathogenic variants in SDHAF2 causing predisposition to PCC/PGL is limited, we discuss the challenges in mutational variant interpretation and decision making regarding screening for associated tumors.
- Open Access
- 21 March 2016
- Published by Wiley in Clinical Endocrinology
- Vol. 85 (1) , 62-69
Are patients with hormonally functional phaeochromocytoma and paraganglioma initially receiving a proper adrenoceptor blockade? A retrospective cohort study
Summary: Objective: Pharmacological treatment is mandatory in patients with hormonally functional phaeochromocytoma and paraganglioma (PHAEO/PGL). We evaluated if patients initially diagnosed with hormonally functional PHAEO/PGL by various medical subspecialties received proper adrenoceptor blockade, and analysed factors predicting the prescription of adequate treatment.Methods: In a retrospective cohort study, we reviewed data from patients initially diagnosed with hormonally functional PHAEO/PGL outside the National Institutes of Health and Cedars‐Sinai Medical Center, who were referred to these institutions between January 2001 and April 2015. Logistic regression was used to assess factors associated with proper adrenoceptor blockade.Results: A total of 381 patients were included. Adequate pharmacological treatment was prescribed to 69·3%, of which 93·1% received α‐adrenoceptor blockers. Regarding patients who were inappropriately treated, 53% did not receive any medication. Independent predictors of the prescription of a proper blockade were the diagnosis by endocrinologists [odds ratio (OR) 4·14; 95% confidence interval (CI), 2·51–6·85; P < 0·001], the presence of high blood pressure (OR 5·94; 95% CI, 3·11–11·33; P < 0·001) and the evidence of metastasis (OR 5·96; 95% CI, 1·93–18·46; P = 0·002).Conclusions: Although most patients received adequate pharmacological treatment, almost one‐third were either not treated or received inappropriate medications. The diagnosis by endocrinologists, the presence of high blood pressure and the evidence of metastatic disease were identified as independent predictors of a proper blockade. These results highlight the need to educate physicians about the importance of starting adequate adrenoceptor blockade in all patients with hormonally functional PHAEO/PGL.
- 21 March 2016
- Published by Wiley in Clinical Endocrinology
- Vol. 85 (1) , 62-69
Open AccessAre patients with hormonally functional phaeochromocytoma and paraganglioma initially receiving a proper adrenoceptor blockade? A retrospective cohort study
Summary: Objective: Pharmacological treatment is mandatory in patients with hormonally functional phaeochromocytoma and paraganglioma (PHAEO/PGL). We evaluated if patients initially diagnosed with hormonally functional PHAEO/PGL by various medical subspecialties received proper adrenoceptor blockade, and analysed factors predicting the prescription of adequate treatment.Methods: In a retrospective cohort study, we reviewed data from patients initially diagnosed with hormonally functional PHAEO/PGL outside the National Institutes of Health and Cedars‐Sinai Medical Center, who were referred to these institutions between January 2001 and April 2015. Logistic regression was used to assess factors associated with proper adrenoceptor blockade.Results: A total of 381 patients were included. Adequate pharmacological treatment was prescribed to 69·3%, of which 93·1% received α‐adrenoceptor blockers. Regarding patients who were inappropriately treated, 53% did not receive any medication. Independent predictors of the prescription of a proper blockade were the diagnosis by endocrinologists [odds ratio (OR) 4·14; 95% confidence interval (CI), 2·51–6·85; P < 0·001], the presence of high blood pressure (OR 5·94; 95% CI, 3·11–11·33; P < 0·001) and the evidence of metastasis (OR 5·96; 95% CI, 1·93–18·46; P = 0·002).Conclusions: Although most patients received adequate pharmacological treatment, almost one‐third were either not treated or received inappropriate medications. The diagnosis by endocrinologists, the presence of high blood pressure and the evidence of metastatic disease were identified as independent predictors of a proper blockade. These results highlight the need to educate physicians about the importance of starting adequate adrenoceptor blockade in all patients with hormonally functional PHAEO/PGL.